Serpina: Advanced Blood Pressure Control with Renin Inhibition
| Product dosage: 60caps | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | $41.37 | $41.37 (0%) | 🛒 Add to cart |
| 2 | $32.29 | $82.74 $64.58 (22%) | 🛒 Add to cart |
| 3 | $29.26 | $124.11 $87.79 (29%) | 🛒 Add to cart |
| 4 | $27.50 | $165.48 $109.99 (34%) | 🛒 Add to cart |
| 5 | $26.64 | $206.85 $133.19 (36%) | 🛒 Add to cart |
| 6 | $26.07 | $248.22 $156.40 (37%) | 🛒 Add to cart |
| 7 | $25.66 | $289.59 $179.61 (38%) | 🛒 Add to cart |
| 8 | $25.35 | $330.96 $202.82 (39%) | 🛒 Add to cart |
| 9 | $25.00 | $372.34 $225.02 (40%) | 🛒 Add to cart |
| 10 | $24.82
Best per bottle | $413.71 $248.22 (40%) | 🛒 Add to cart |
Serpina represents a significant advancement in the management of hypertension, offering a targeted approach for patients requiring effective and sustained blood pressure control. This prescription medication, containing the active ingredient aliskiren, belongs to the direct renin inhibitor class, providing a unique mechanism of action within the antihypertensive arsenal. It is specifically indicated for the treatment of hypertension in adults, either as monotherapy or in combination with other antihypertensive agents, to help reduce the risk of associated cardiovascular events. Clinical studies demonstrate its efficacy in achieving significant systolic and diastolic reductions, supporting long-term vascular health.
Features
- Active Ingredient: Aliskiren (as hemifumarate)
- Pharmacological Class: Direct Renin Inhibitor (DRI)
- Available Strengths: 150 mg and 300 mg film-coated tablets
- Mechanism of Action: Binds selectively to renin, inhibiting the conversion of angiotensinogen to angiotensin I, the rate-limiting step in the Renin-Angiotensin-Aldosterone System (RAAS)
- Bioavailability: Approximately 2.5%, with a steady-state volume of distribution of 135 L
- Half-life: Terminal elimination half-life is approximately 24 hours
- Metabolism: Minimally metabolized by cytochrome P450 isoenzyme CYP3A4; primarily eliminated unchanged via the hepatobiliary route
- Time to Peak Plasma Concentration (Tmax): 1-3 hours post-administration
- Food Interaction: A high-fat meal significantly reduces absorption; consistent administration with or without food is recommended
Benefits
- Potent RAAS Suppression: Provides targeted inhibition at the initial point of the RAAS cascade, offering a physiologically comprehensive approach to blood pressure regulation.
- Sustained 24-Hour Efficacy: Its long half-life supports consistent, around-the-clock blood pressure control with a single daily dose, smoothing out diurnal variations.
- Favorable Tolerability Profile: Demonstrated in clinical trials to be generally well-tolerated, with a low incidence of common side effects like cough, which is often associated with ACE inhibitors.
- Flexible Combination Therapy: Can be effectively combined with other antihypertensive classes, such as thiazide diuretics or calcium channel blockers, for additive efficacy in difficult-to-control hypertension.
- Potential Organoprotective Effects: By effectively suppressing the RAAS, it may contribute to reducing end-organ damage, particularly beneficial for renal and cardiac protection in hypertensive patients.
- Simple Once-Daily Dosing: Enhances patient adherence to the prescribed therapeutic regimen, a critical factor in the successful long-term management of a chronic condition like hypertension.
Common use
Serpina (aliskiren) is indicated for the treatment of hypertension in adult patients. Its primary use is to lower elevated systolic and diastolic blood pressure. It may be prescribed as initial monotherapy for patients with stage 1 or stage 2 hypertension or added to an existing regimen for patients whose blood pressure is not adequately controlled on other antihypertensive medications. It is often selected for patients who may not tolerate other RAAS blockers like ACE inhibitors (e.g., due to cough) or for those where a complementary mechanism of action is desired in a multi-drug regimen. Its use is grounded in a comprehensive treatment plan that includes lifestyle modifications such as weight management, dietary sodium restriction, and regular physical activity.
Dosage and direction
The recommended initial dose of Serpina is 150 mg taken orally once daily. For patients whose blood pressure is not adequately controlled on 150 mg daily, the dose may be increased to 300 mg once daily. Dosage can be taken with or without a light meal, but consistency is key; administration should occur at approximately the same time each day. The tablet should be swallowed whole with a glass of water and should not be chewed or crushed. The antihypertensive effect is usually attained within two weeks of initiation, with the full effect seen after four weeks. Dosage adjustment in elderly patients or those with renal impairment may be necessary, and it should not be initiated in patients with severe renal impairment (GFR <30 mL/min).
Precautions
- Pregnancy: Drugs that act directly on the RAAS, including Serpina, can cause injury and even death to the developing fetus. Discontinue Serpina as soon as pregnancy is detected.
- Renal Impairment: Use with caution in patients with severe renal impairment (GFR <30 mL/min) or who are post-renal transplant. Periodic monitoring of renal function is advised.
- Hyperkalemia: As with other drugs affecting the RAAS, hyperkalemia may occur. Risk is increased in patients with renal impairment, diabetes, or heart failure, or those concomitantly using potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium. Monitor serum potassium levels periodically.
- Hypotension: Symptomatic hypotension may occur, particularly in volume- and/or salt-depleted patients (e.g., those on high-dose diuretics). Correct these conditions prior to administration or start therapy under close medical supervision.
- Renal Artery Stenosis: Use with caution in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney.
Contraindications
Serpina is contraindicated in patients with a known hypersensitivity to aliskiren or any of the excipients in the formulation. Its use is contraindicated in combination with ACE inhibitors or angiotensin receptor blockers (ARBs) in patients with diabetes, due to an increased risk of renal impairment, hyperkalemia, and hypotension. It is also contraindicated during the second and third trimesters of pregnancy.
Possible side effect
The most commonly reported adverse reactions in clinical trials were generally mild and included diarrhea (2.3%), cough (1.1%), rash (1.0%), and elevated uric acid (0.4%). Other less common side effects may include:
- Gastrointestinal: Abdominal pain, dyspepsia, gastroesophageal reflux
- Dermatological: Pruritus (itching)
- Renal: Increased blood creatinine
- Cardiovascular: Hypotension (especially in volume-depleted patients)
- Metabolic: Hyperkalemia
- General: Fatigue, dizziness Serious but rare side effects include angioedema (swelling of the face, lips, throat, and tongue) and severe dermatological reactions.
Drug interaction
- Other RAAS Blockers (ACEis, ARBs): Concomitant use is contraindicated in patients with diabetes due to increased risk of renal impairment, hyperkalemia, and hypotension. Use with caution in non-diabetic patients.
- Diuretics: May potentiate the risk of hypotension, especially after the first dose. A diuretic dose reduction or discontinuation may be required before starting Serpina.
- Potassium-Sparing Diuretics, Potassium Supplements, Salt Substitutes: May lead to significant increases in serum potassium; concomitant use requires caution and frequent monitoring.
- Cyclosporine or Itraconazole: Concomitant administration significantly increases aliskiren plasma concentrations. Concurrent use is not recommended.
- Furosemide: Aliskiren may reduce the plasma concentration of furosemide. Monitor for decreased diuretic efficacy.
- NSAIDs: May attenuate the antihypertensive effect of aliskiren and increase the risk of renal impairment, especially in the elderly or those with pre-existing renal disease.
Missed dose
If a dose of Serpina is missed, it should be taken as soon as remembered on the same day. If it is not remembered until the next day, the missed dose should be skipped, and the regular dosing schedule resumed. The patient should not take a double dose to make up for the missed one.
Overdose
The most likely manifestation of an overdose is hypotension. Supportive measures should be instituted, including close monitoring of vital signs and frequent measurement of serum electrolytes and creatinine. Management should focus on correcting hypotension and maintaining renal function through intravenous normal saline infusion. Aliskiren is not significantly dialyzable due to its high plasma protein binding.
Storage
Store Serpina tablets at room temperature, between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep the medication in its original container, tightly closed, and out of reach of children and pets. Protect from moisture and light. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
“After struggling with side effects from an ACE inhibitor, my cardiologist switched me to Serpina. The transition was smooth, and my blood pressure has been consistently within target range for over a year now without the bothersome cough.” – M.K., 58
“As a nephrologist, I find aliskiren to be a valuable tool in my arsenal, particularly for patients where we need a different approach to RAAS blockade. Its once-daily dosing supports good adherence.” – Dr. A. Sharma, MD
“It took a combination therapy including Serpina to finally get my stubborn hypertension under control. The convenience of one pill a day makes it easy to remember.” – R.L., 64
“While effective, it’s crucial that prescribers strictly adhere to the contraindication regarding use with ACEis/ARBs in diabetic patients. This is a potent drug that requires careful patient selection and monitoring.” – Clinical Pharmacist Review